Engineered immune cells, particularly chimeric antigen receptor (CAR) T cells, have shown remarkable potential in revolutionizing the treatment of blood cancers. However, these powerful tools come with significant limitations. Their effectiveness is often restricted to hematological malignancies, while solid tumors remain largely resistant. Additionally, there is a risk of CAR T cells inadvertently targeting healthy cells or causing severe immune reactions, leading to critical side effects.
Addressing CAR T Cell Challenges
To overcome these issues, a team of researchers from Ludwig Lausanne, led by Melita Irving and Greta Maria Paola Giordano Attianese, along with colleagues from the École Polytechnique Fédérale de Lausanne (EPFL), have pioneered a groundbreaking approach. They have developed a CAR T cell that can be easily switched off on demand, offering a promising solution to enhance safety and efficacy. Their findings, recently published in a leading scientific journal, showcase the design and preclinical evaluation of these innovative CAR T cells in mouse cancer models.
The team’s novel system employs venetoclax, a drug already established in clinical use, as a remote control to manage CAR T cell activation. Unlike previous methods that often led to the destruction of CAR T cells, this approach allows them to simply disengage from their cancer targets, providing clinicians with a versatile tool to modulate therapy effectively.
Mechanism of Action
Traditional CAR T cells utilize a receptor that protrudes from the engineered T cell, designed to identify and bind to specific cancer cell antigens. Upon detection, this binding initiates a cascade of internal signals, activating the T cell’s cytotoxic mechanisms to attack cancer cells. The internal signaling components consist of critical protein domains, including CD3-ζ, which is essential for T cell activation, and co-stimulatory proteins that enhance T cell longevity and performance.
In their previous work, Irving and Giordano Attianese developed a method to control CAR T cell activity by disconnecting the internal signaling chain from the receptor. This system required another drug to facilitate the degradation of the signaling component, effectively turning off the CAR T cells. However, their latest innovation, known as the “drug-regulated off-switch PPI CAR” (DROP-CAR), redefines this approach.
The DROP-CAR Innovation
The DROP-CAR incorporates a switch on the exterior of the T cell. The internal signaling component is linked to an external protein strip that carries a specially designed human domain, dmLD3. This domain binds tightly to a protein called BCL-2, which is also present on the CAR’s cancer-sensing antibody. This intelligent design relies on spontaneous protein-protein interactions to maintain CAR functionality. When venetoclax is administered, it disrupts this interaction, causing the CAR to disassemble and effectively turning off the CAR T cell’s activity.
Upon withdrawal of venetoclax, the CAR reassembles, reactivating the T cells to resume their attack on cancer cells. This innovative mechanism allows for precise control over CAR T cell activity without sacrificing their therapeutic potential.
Enhanced Safety Profile
One of the standout features of the DROP-CAR system is its reliance solely on human protein components and a clinically approved drug that does not suppress the immune system. This direct disruption of tumor cell binding enhances the safety profile of CAR T therapy. By acting at the level of cell contact rather than within the cell, it minimizes risks associated with signaling blockages, degradation, or cell death, preserving CAR T cells for ongoing treatment.
Mitigating T Cell Exhaustion
Another significant advantage of this controllable CAR T cell design is its potential to address T cell “exhaustion.” This phenomenon can limit the effectiveness of many immunotherapies, as continuous stimulation in the tumor’s immunosuppressive environment can lead T cells to enter a state where they lose their ability to function effectively. Research has shown that allowing CAR T cells periods of rest can reverse the changes that contribute to exhaustion, enhancing their overall efficacy. The DROP-CAR system is well-suited to facilitate this approach.
Path to Clinical Evaluation
Given that venetoclax is already approved for cancer treatment, the DROP-CAR system is uniquely positioned for rapid clinical evaluation. The researchers believe that this novel approach could broaden the applicability of CAR T therapy to more patients and diverse cancer types, ultimately improving outcomes in the fight against cancer.
Key Takeaways
- Innovative Control: The DROP-CAR system allows for on-demand control of CAR T cells using venetoclax, enhancing safety and effectiveness.
-
Mechanism: This technology leverages protein-protein interactions to maintain CAR functionality, allowing for reactivation after treatment.
-
Safety Improvements: The use of human proteins and a non-immunosuppressive drug reduces risks associated with traditional CAR T therapies.
-
Combating Exhaustion: The DROP-CAR design may help reverse T cell exhaustion, potentially improving therapy outcomes.
-
Clinical Readiness: With an approved drug as part of the system, DROP-CARs are primed for clinical trials.
In summary, the innovation surrounding remote-controlled CAR T cells represents a pivotal advancement in cancer therapy, addressing significant challenges while enhancing safety and efficacy. This exciting development holds promise for transforming treatment paradigms and expanding the benefits of CAR T cell therapy to a wider range of cancer patients.
Read more → www.news-medical.net